KR20250151559A - 프로그램 가능한 면역세포 수용체 복합체 시스템 - Google Patents

프로그램 가능한 면역세포 수용체 복합체 시스템

Info

Publication number
KR20250151559A
KR20250151559A KR1020257032463A KR20257032463A KR20250151559A KR 20250151559 A KR20250151559 A KR 20250151559A KR 1020257032463 A KR1020257032463 A KR 1020257032463A KR 20257032463 A KR20257032463 A KR 20257032463A KR 20250151559 A KR20250151559 A KR 20250151559A
Authority
KR
South Korea
Prior art keywords
cell
programmable
cells
ser
receptor complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257032463A
Other languages
English (en)
Korean (ko)
Inventor
위안위안 탕
조셉 디. 키틀
조엘 에스. 르완드
성원 롄
Original Assignee
펀다멘탈 솔류션스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 펀다멘탈 솔류션스 코포레이션 filed Critical 펀다멘탈 솔류션스 코포레이션
Publication of KR20250151559A publication Critical patent/KR20250151559A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/36—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Actinomyces; from Streptomyces (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/22—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a Strep-tag
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dermatology (AREA)
KR1020257032463A 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템 Pending KR20250151559A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862643378P 2018-03-15 2018-03-15
US62/643,378 2018-03-15
US201862651916P 2018-04-03 2018-04-03
US62/651,916 2018-04-03
PCT/US2019/022245 WO2019178342A1 (en) 2018-03-15 2019-03-14 Programmable immunocyte receptor complex system
KR1020207029506A KR102867256B1 (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020207029506A Division KR102867256B1 (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Publications (1)

Publication Number Publication Date
KR20250151559A true KR20250151559A (ko) 2025-10-21

Family

ID=67905164

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257032463A Pending KR20250151559A (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템
KR1020207029506A Active KR102867256B1 (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020207029506A Active KR102867256B1 (ko) 2018-03-15 2019-03-14 프로그램 가능한 면역세포 수용체 복합체 시스템

Country Status (6)

Country Link
US (3) US20190284255A1 (https=)
EP (1) EP3765093A4 (https=)
JP (1) JP7462578B2 (https=)
KR (2) KR20250151559A (https=)
CN (1) CN112955184A (https=)
WO (1) WO2019178342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11117936B2 (en) * 2017-11-10 2021-09-14 University of Pittsburg—Of the Commonwealth System of Higher Education Affinity-enhanced monomeric streptavidin chimeric antigen receptor (CAR)
CN112955184A (zh) 2018-03-15 2021-06-11 基本解决方案公司 可编程免疫细胞受体复合物系统
US20220242929A1 (en) * 2019-08-05 2022-08-04 Cartherics Pty. Ltd. Immune cells expressing modified cell receptors and methods of making

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874239A (en) 1993-07-30 1999-02-23 Affymax Technologies N.V. Biotinylation of proteins
GB9721075D0 (en) * 1997-10-03 1997-12-03 Cancer Res Campaign Tech Materials and methods relating to the stimulation of cells
FI20021518A0 (fi) * 2002-08-23 2002-08-23 Jyvaeskylaen Yliopisto Avidiinin lämpökestävyyden lisääminen
WO2013044225A1 (en) * 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
JP2015524255A (ja) * 2012-07-13 2015-08-24 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 二重特異性抗体を共導入することによってｃａｒｔ細胞の活性を強化する方法
WO2014055442A2 (en) * 2012-10-01 2014-04-10 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
NZ759969A (en) * 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
CA2964958A1 (en) * 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
US9752199B2 (en) 2015-03-31 2017-09-05 Fundamental Solutions Corporation Biosensor system for the rapid detection of analytes
ES2893879T3 (es) * 2015-03-31 2022-02-10 Fundamental Solutions Corp Sistema biosensor para la detección rápida de analitos
WO2016196384A1 (en) * 2015-05-29 2016-12-08 Fred Hutchinson Cancer Research Center Compositions for cellular immunotherapy
US12121539B2 (en) * 2015-09-11 2024-10-22 Biosceptre (Aust) Pty Ltd Chimeric antigen receptors and uses thereof
CN109562126A (zh) * 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 嵌合抗原受体(car)、组合物及其使用方法
CN112955184A (zh) 2018-03-15 2021-06-11 基本解决方案公司 可编程免疫细胞受体复合物系统

Also Published As

Publication number Publication date
KR102867256B1 (ko) 2025-10-01
CN112955184A (zh) 2021-06-11
US12234273B2 (en) 2025-02-25
EP3765093A1 (en) 2021-01-20
EP3765093A4 (en) 2021-12-08
US20200299352A1 (en) 2020-09-24
WO2019178342A1 (en) 2019-09-19
JP7462578B2 (ja) 2024-04-05
JP2021518428A (ja) 2021-08-02
KR20210018196A (ko) 2021-02-17
US20190284255A1 (en) 2019-09-19
US20250197472A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US11266690B2 (en) Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof
US20210236650A1 (en) Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
US20250197472A1 (en) Programmable immunocyte receptor complex system
AU2019275479B2 (en) Chimeric antigen receptors with modified linker domains and uses thereof
US10053514B2 (en) Human bispecific EGFRvIII and CD3 antibody engaging molecules
AU2020332969A1 (en) Anti-PD-L1 single domain antibodies
US9676858B2 (en) Human bispecific EGFRvIII antibody and CD3 engaging molecules
AU2017209313A1 (en) ROR2 antibody compositions and related methods
KR20200028447A (ko) 피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
JP2021515574A (ja) 誘導性ｔ細胞レセプター及びその使用
KR20220122844A (ko) Cd22에 특이적인 인간화 항체 및 이의 용도
CN114685659B (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体
EP4286520A1 (en) Antigen binding protein and use thereof
CN116284389A (zh) 抗afp/hla02 tcr样抗体及其用途
US20260007749A1 (en) Chimeric antigen receptor with increased affinity for mesothelin and use thereof
US20250213691A1 (en) Antigen binding protein targeting msln and use thereof
EP4620974A1 (en) Anti-afp/hla02 tcr-like antibody and use thereof
US20250333514A1 (en) Antigen binding proteins targeting an hla-restricted prame peptide
RU2784586C2 (ru) Человеческие антитела, связывающиеся с ror2
WO2024088371A1 (zh) 靶向msln的抗原结合蛋白
WO2024169985A1 (zh) 靶向HER2/p95HER2的P329G抗体及其与嵌合抗原受体细胞的组合和应用
CN121511260A (zh) SLC4A4/NBCe1抑制剂
CN118005800A (zh) 多特异性抗体结构
HK40067100A (zh) Cd22特异性人源化抗体及利用其的嵌合抗原受体

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000